Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Pedro Cascales Campos, MD,PhD
CONTACT
Lead
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Peritoneal carcinomatosis arising from ovarian epithelial carcinoma (stage III or higher), carcinoma of the fallopian tube and primary peritoneal carcinoma.
Residual tumor \< 2.5 mm after completion of cytoreductive surgery.
Adequate bone marrow function with hemoglobin ? 8 g/dl (after correction for iron deficiency anemia), white blood cell count ? 3,000/mm3, platelets ? 100,000/mm3.
Adequate renal function with creatinine ? 1.5 mg/ dl.
Adequate liver function with bilirubin levels ? 1.5 mg / dl and AST and ALT ? 80 IU / L.
Optimal cardiopulmonary function.
In recurrences, disease-free interval \> 6 months.
Voluntary and signed written informed consent.
You may not be if
Extraperitoneal tumor disease.
Suboptimal debulking (residual tumor \> 2.5 mm).
Previous history of other malignancies (excluding skin)
Intestinal obstruction at the time of evaluation.
Renal failure.
Heart failure.
Uncontrolled infection.
Pregnant or lactating patients.
In recurrences, disease-free interval \< 6 months.
Clareo Health | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma
